Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | GCK | P35557 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737306 | 0.84 | MMP13 (0.58) | RAF1LMNAPOLBMAPK14MEN1 | |
| SCHEMBL8737464 | 0.83 | SMN1; SMN2 (0.61) | RAF1LMNAPOLBMAPK14MEN1 | |
| SCHEMBL8737301 | 0.82 | FFAR1 (0.69) | RAF1MEN1KMT2AHDAC8SMN1; SMN2 | |
| SCHEMBL8738321 | 0.81 | MAPK14 (0.76) | RAF1LMNAMAPK14KMT2AHDAC8 | |
| SCHEMBL8736963 | 0.81 | MMP13 (0.56) | RAF1LMNAMAPK14MEN1KMT2A | |
| SCHEMBL12093592 | 0.80 | LMNA (0.78) | LMNAPOLBMAPK14MEN1KMT2A | |
| SCHEMBL14336245 | 0.79 | ALDH1A1 (0.64) | RAF1LMNAPOLBMEN1KMT2A | |
| SCHEMBL14684329 | 0.77 | NR1H4 (0.71) | LMNAPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28412237 | 0.77 | HDAC8 (0.63) | LMNAMEN1KMT2AHDAC8SMN1; SMN2 | |
| SCHEMBL11668725 | 0.76 | HDAC8 (0.67) | RAF1LMNAMEN1KMT2AHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381177-B2 | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| US-9381177-B2 | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| WO-2007053574-A2 | COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | RAF1 51/4885LMNA 4309/4885POLB 1892/4885 |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | MAPK1, MAPK8, MAPK3 | RAF1 452/4885LMNA 2805/4885POLB 3099/4885 |
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | KIT, CHUK, IKBKB | RAF1 532/4885LMNA 1562/4885POLB 990/4885 |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | RAF1 2/4885LMNA 3637/4885POLB 2254/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885LMNA 3377/4885POLB 2564/4885 |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885LMNA 3199/4885POLB 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.